Arrowhead Pharmaceuticals, Inc.
ARWR
Jodie situation report
Arrowhead Pharmaceuticals, Inc.'s move is being confirmed by its market group.
ARWR accounts for 1.1% of the group's measured movement across 6.0 effective names. raw member direction is mixed; 6 of 8 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
ROIV, IBRX, BBIO moved materially before ARWR. ARWR crossed its material path threshold at 11:10 ET, 5 minutes after the first measured mover. CGON, BEAM followed.
5 of 8 members in Gene Editing Therapies are active. 0 of 8 disclosed connections are confirming.
- At least 6 of 8 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as RLYB begins moving with the group.
Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.
Who this business touches
The relationships behind ARWR
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
NVSNovartis AGpartnerFeb 5, 2026 ▾
“Over the past several years we have entered into license and collaboration agreements with Takeda, Janssen, Amgen, Horizon, GSK, Sarepta, Visirna and Novartis Pharma AG (“Novartis”).”
SNYSanofipartnerFeb 5, 2026 ▾
“Under our licensing and collaboration agreements with Amgen, Takeda, GSK, Sarepta, Visirna, Sanofi, and Novartis, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements in their r…”
Depended on by
AKBAAkebia Therapeutics, Inc.partnerFeb 26, 2026 ▾
“A number of complement inhibitors are in development for the treatment of IgAN by companies including Alexion Pharmaceuticals, (ULTOMIRIS, ravulizumab, C5 inhibitor, Phase 3), Apellis (EMPAVELI, pegcetacoplan, C3 inhibitor, Phase 2), and Arrowhead Pharmaceuti…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ARWR is currently a Participant in the organic co-movement group Gene Editing Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.